newest glp 1 drug Eli Lilly to seek approval of new GLP-1 weight-loss this year World Health Organization recommends GLP-1

DPP4 inhibitors anti-fibrotic activities have also been demonstrated in various renal fibrosis models, such as the unilateral ureteral obstruction (UUO) model

Other combinations have reached as much as 20 percent on higher doses

Diabetologia 57 , 24752484 (2014)

Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

Four published studies showed no pancreatitis effects including one in which the pancreas of rats, mice and monkeys showed no change with liraglutide at concentrations 60 fold higher than used in humans for up to two years (86)

Some outcomes are already supported by large trials